brano-mm1vipqd0oa-unsplash

Vertex Pharmaceuticals and CRISPR Therapeutics submit FDA rolling Biologics License Applications for gene editing-based medicine

April 4, 2023
Research and Development

US-based Vertex Pharmaceuticals and Swiss CRISPR Therapeutics have announced the completion of their rolling Biologics License Applications (BLAs) to the …

towfiqu-barbhuiya-6f2mpewg2ra-unsplash

FDA publishes report stating Global Pharma’s eye drops broke safety norms

April 4, 2023
Medical Communications

The FDA has published a report revealing that Global Pharma’s plant in India’s Chennai city failed to achieve safety norms …

james-yarema-5tymgag0wro-unsplash_1

InnoCare announced first subject dosed in clinical trial of novel targeted protein degrader ICP-490

April 4, 2023
Medical Communications

InnoCare has announced that the first subject has been dosed in its clinical trial of its novel targeted protein degrader …

Merck receives FDA approval for Keytruda in combination with Padcev to treat bladder cancer

April 4, 2023
Medical Communications

Merck (known as MSD globally) has announced that it has received FDA approval for Keytruda in combination with Padcev for …

Théa Open Innovation and Galimedix announce partnership for development and commercialisation of GAL-101

April 3, 2023
Sales and Marketing

Théa Open Innovation (TOI) and Galimedix have announced that they have signed a licensing agreement granting TOI exclusive rights for …

ed-us-k0dml4nmopo-unsplash

aVaxziPen announces positive data for multiple diseases with novel needle-free vaccine

April 3, 2023
Research and Development

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will …

david-travis-avvzjc0ynbq-unsplash_1

Pixium Vision’s Prima System granted FDA Breakthrough Device Designation

April 3, 2023
Medical Communications

French bioelectronics company Pixium Vision has been granted Breakthrough Device Designation by the FDA for its Prima System.   Prima …

pawel-czerwinski-kxblpqfyc9e-unsplash

AstraZeneca’s NMOSD treatment recommended marketing authorisation by CHMP

April 3, 2023
Medical Communications

Pharma giant AstraZeneca has been given a recommendation by the EU’s Committee for Medicinal Products (CHMP) for marketing authorisation for …

CrestOptics launches CICERO system to provide all-in-one solution for widefield and spinning disk confocal microscopy

April 3, 2023
Business Services

Rome, IT, 03 April, 2023: CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and …

Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure

April 3, 2023
Business Services

Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana

Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)

April 3, 2023
Business Services

Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases …

Redx Confirms Proposed Business Combination with Jounce has Formally Lapsed

April 3, 2023
Business Services

Alderley Park, UK, 3 April 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

March 31, 2023
Business Services

Hong Kong, Shanghai & Florham Park, NJ — Friday, March 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that …

Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease

March 31, 2023
Medical Communications

Abbott has announced that the FDA has approved its Epic Max stented tissue valve to treat patients with aortic regurgitation …

First over-the-counter opioid overdose treatment approved by FDA

March 31, 2023
Medical Communications

The FDA has announced that it has approve Narcan, 4mg naloxone hydrochloride nasal spray for over-the-counter (OTC), non-prescription use. This …

NEC streamlines AI drug development with subsidiary reshuffle

March 31, 2023
Medical Communications

Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. …

Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa

March 31, 2023
Medical Communications

US-based Nanoscope Therapeutics has announced topline results from its phase 2b RESTORE clinical trial. Currently, patients with vision loss due …

Expansion of Scientific Affairs Group

March 30, 2023
Business Services

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …

Roz Bekker appointed Managing Director of Janssen UK & Ireland

March 30, 2023
Business Services

High Wycombe, UK, 30 March 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to introduce Roz …

The Gateway to Local Adoption Series

Latest content